Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody.

Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S.

PLoS Biol. 2019 Jun 19;17(6):e3000323. doi: 10.1371/journal.pbio.3000323. eCollection 2019 Jun.

2.

Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces.

Strasser J, de Jong RN, Beurskens FJ, Wang G, Heck AJR, Schuurman J, Parren PWHI, Hinterdorfer P, Preiner J.

Nano Lett. 2019 Jul 10;19(7):4787-4796. doi: 10.1021/acs.nanolett.9b02220. Epub 2019 Jun 11.

PMID:
31184907
3.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP.

Haematologica. 2019 Feb 21. pii: haematol.2018.207266. doi: 10.3324/haematol.2018.207266. [Epub ahead of print]

4.

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

Engelberts PJ, Breij ECW, Valerius T, Schuurman J, Parren PWHI, Beurskens FJ.

J Immunol. 2018 Apr 15;200(8):2517. doi: 10.4049/jimmunol.1800233. No abstract available.

5.

Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement.

Ugurlar D, Howes SC, de Kreuk BJ, Koning RI, de Jong RN, Beurskens FJ, Schuurman J, Koster AJ, Sharp TH, Parren PWHI, Gros P.

Science. 2018 Feb 16;359(6377):794-797. doi: 10.1126/science.aao4988.

PMID:
29449492
6.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

7.

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.

Losen M, Labrijn AF, van Kranen-Mastenbroek VH, Janmaat ML, Haanstra KG, Beurskens FJ, Vink T, Jonker M, 't Hart BA, Mané-Damas M, Molenaar PC, Martinez-Martinez P, van der Esch E, Schuurman J, de Baets MH, Parren PWHI.

Sci Rep. 2017 Apr 20;7(1):992. doi: 10.1038/s41598-017-01019-5.

8.

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PW, Valerius T.

J Immunol. 2017 Feb 15;198(4):1585-1594. doi: 10.4049/jimmunol.1601268. Epub 2017 Jan 6.

9.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.

J Immunol. 2016 Dec 15;197(12):4829-4837. Epub 2016 Nov 2.

10.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP.

J Immunol. 2016 Sep 1;197(5):1762-75. doi: 10.4049/jimmunol.1600648. Epub 2016 Jul 29.

11.

Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.

Wang G, de Jong RN, van den Bremer ET, Beurskens FJ, Labrijn AF, Ugurlar D, Gros P, Schuurman J, Parren PW, Heck AJ.

Mol Cell. 2016 Jul 7;63(1):135-45. doi: 10.1016/j.molcel.2016.05.016. Epub 2016 Jun 16.

12.

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, Heck AJ, Schuurman J, Parren PW.

PLoS Biol. 2016 Jan 6;14(1):e1002344. doi: 10.1371/journal.pbio.1002344. eCollection 2016 Jan.

13.

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP.

Mol Immunol. 2016 Feb;70:13-23. doi: 10.1016/j.molimm.2015.12.007. Epub 2015 Dec 12.

PMID:
26690706
14.

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.

Derer S, Cossham M, Rösner T, Kellner C, Beurskens FJ, Schwanbeck R, Lohse S, Sina C, Peipp M, Valerius T.

J Immunol. 2015 Nov 15;195(10):5077-87. doi: 10.4049/jimmunol.1501458. Epub 2015 Oct 16.

15.

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.

van den Bremer ET, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, Parren PW.

MAbs. 2015;7(4):672-80. doi: 10.1080/19420862.2015.1046665.

16.

C1q, antibodies and anti-C1q autoantibodies.

Beurskens FJ, van Schaarenburg RA, Trouw LA.

Mol Immunol. 2015 Nov;68(1):6-13. doi: 10.1016/j.molimm.2015.05.010. Epub 2015 May 29. Review.

PMID:
26032012
17.

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW.

Mol Immunol. 2015 Oct;67(2 Pt A):117-30. doi: 10.1016/j.molimm.2015.01.028. Epub 2015 Feb 17. Review.

18.

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ, Golay J.

Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.

19.

Complement in antibody-based tumor therapy.

Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T.

Crit Rev Immunol. 2014;34(3):199-214. Review.

PMID:
24941073
20.

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW.

Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943.

21.

A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab.

Engelberts PJ, Badoil C, Beurskens FJ, Boulay-Moine D, Grivel K, Parren PW, Moulard M.

J Immunol Methods. 2013 Feb 28;388(1-2):8-17. doi: 10.1016/j.jim.2012.11.007. Epub 2012 Nov 24.

PMID:
23183273
22.

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M.

Leukemia. 2013 Jan;27(1):190-201. doi: 10.1038/leu.2012.150. Epub 2012 Jun 4.

PMID:
22660187
23.

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.

Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP.

J Immunol. 2012 Apr 1;188(7):3532-41. doi: 10.4049/jimmunol.1103693. Epub 2012 Feb 24.

24.

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH.

Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31.

25.

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP.

J Immunol. 2011 Sep 15;187(6):3438-47. doi: 10.4049/jimmunol.1101189. Epub 2011 Aug 12.

26.

Complement activation by (auto-) antibodies.

Daha NA, Banda NK, Roos A, Beurskens FJ, Bakker JM, Daha MR, Trouw LA.

Mol Immunol. 2011 Aug;48(14):1656-65. doi: 10.1016/j.molimm.2011.04.024. Epub 2011 Jul 14. Review.

PMID:
21757235
27.

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.

Beum PV, Lindorfer MA, Peek EM, Stukenberg PT, de Weers M, Beurskens FJ, Parren PW, van de Winkel JG, Taylor RP.

Eur J Immunol. 2011 Aug;41(8):2436-46. doi: 10.1002/eji.201041204. Epub 2011 Jul 4.

28.

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH.

Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30.

29.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP.

J Immunol. 2009 Jul 1;183(1):749-58. doi: 10.4049/jimmunol.0900632. Epub 2009 Jun 17.

30.

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.

Beurskens FJ, Ruuls SR, Engelberts PJ, Vink T, Mackus WJ, van de Winkel JG, Parren PW.

Blood. 2008 Nov 15;112(10):4354-5; author reply 4355-6. doi: 10.1182/blood-2008-07-171082. No abstract available.

31.

IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis.

Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot EP, Hudson D, Baadsgaard O, Parren PW, van de Winkel JG.

J Immunol. 2008 Jul 1;181(1):669-79.

32.

Fc receptor but not complement binding is important in antibody protection against HIV.

Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.

Nature. 2007 Sep 6;449(7158):101-4.

PMID:
17805298
33.

Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35).

Chen CH, Ghiran I, Beurskens FJ, Weaver G, Vincent JA, Nicholson-Weller A, Klickstein LB.

Clin Exp Immunol. 2007 Jun;148(3):546-54.

34.

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.

Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW, Gracie JA, Jongbloed S, Liew FY, McInnes IB.

Arthritis Rheum. 2005 Sep;52(9):2686-92.

35.

Manifestations of inflammatory arthritis are critically dependent on LFA-1.

Watts GM, Beurskens FJ, Martin-Padura I, Ballantyne CM, Klickstein LB, Brenner MB, Lee DM.

J Immunol. 2005 Mar 15;174(6):3668-75.

36.

A role for lipid rafts in C1q-triggered O2- generation by human neutrophils.

Otabor I, Tyagi S, Beurskens FJ, Ghiran I, Schwab P, Nicholson-Weller A, Klickstein LB.

Mol Immunol. 2004 Jun;41(2-3):185-90.

PMID:
15159064
37.

Mouse complement components C4 and Slp act synergistically in a homologous hemolytic C4 assay.

Beurskens FJ, Tosi M, Shiroisho T, Robins DM, Carroll MC, van Dijk H.

Eur J Immunol. 2000 May;30(5):1507-11.

38.

Sex-limited protein: in vitro and in vivo functions.

Beurskens FJ, Kuenen JD, Hofhuis F, Fluit AC, Robins DM, Van Dijk H.

Clin Exp Immunol. 1999 Jun;116(3):395-400.

39.
40.

Does complement component C4A protect from autoimmune disease?

Beurskens FJ, van Dijk H, Robins DM.

Immunol Today. 1997 Apr;18(4):199. No abstract available.

PMID:
9136457

Supplemental Content

Loading ...
Support Center